Roivant reports preliminary Q3 cash ~$1.5B; VTAMA revenue guided $9.0-9.5M

Roivant Sciences Ltd.

2022-Q3 EPS reported -$1.39 revenue$33,904,000

Cash, cash equivalents and restricted cash ~$1.5B at Dec 31, 2022; pro-forma $1.7B after expected $115M Myovant proceeds.
Net product revenues from VTAMA expected $9.0M to $9.5M for Q3 ending Dec 31, 2022.
Myovant transaction with Sumitomo Pharma expected to close by March 31, 2023.
Preliminary unaudited results; final Q3 2022 financials to be reported in subsequent SEC filing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Roivant Sciences Ltd. reported the third quarter ended December 31, 2022 results: revenue between $9.0 million and $9.5 million.

Period: the third quarter ended December 31, 2022
Revenue: between $9.0 million and $9.5 million
Result: preliminary results

Exact text from the filing

In addition, for the third quarter ended December 31, 2022, the Company expects to report between $9.0 million and $9.5 million in net product revenues from VTAMA. This information is preliminary and unaudited and reflects the Company’s estimated financial results.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Roivant Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001140361-23-003906

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.